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Several interventions have been implemented for control and prevention of 
HIV, including provision of Antiretroviral Therapy (ART). A major concern is how 
this investment can effectively reduce morbidity and mortality due to HIV given 
the existence of various factors that contribute to treatment failure. The purpose 
of this chapter is to elaborate the role of gender on HIV Disease progression and 
treatment outcomes. Demographic, epidemiological, clinical, immunological, 
treatment information as well as  blood from HIV infected patients were collected. 
Epidemiological analyses, using standard phylogenetic and statistical tests were 
done. A follow-up of patients who were initiated on ART for 1 year enabled descrip-
tion of the gender differences in HIV disease progression and treatment outcome. 
After 1 year of follow up on ART, more females survived, and more females had 
undetectable viral load compared to males. However, women lost their initial 
immunological advantage as they presented with lower immunological recovery 
after 1 year of therapy. Socio-demographic factors do have an impact on disease 
progression during ART in HIV-1 infected patients. We recommend that more 
cohorts of patients be continuously followed up to understand the differences on 
ART outcome between males and females.
Keywords: gender differences, HIV, disease progression, treatment outcomes, 
Tanzania
1. Introduction
The epidemic of the Acquired Immune Deficiency Syndrome (AIDS) was first 
recognized as a clinical entity in 1981 [1]. HIV-1 was identified as the causative 
agent for AIDS in 1983 [2]. Globally, 37.9 million people were living with HIV, with 
1.7 million new infections and 770,000 people having died of AIDS in 2018. Sub-
Saharan Africa is the most severely affected by HIV infection in which 1 in every 20 
adults (4.9%) are living with HIV [3].
HIV may be classified into types, groups and subtypes based on genetic similari-
ties. There are two types of HIV: HIV-1 and HIV-2. Both types can be transmitted 
by sexual contact, blood contact, and vertical from mother to child [4]. HIV-1 is 
the predominant type worldwide with high genetic diversity due to extremely high 
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mutation and recombination rates and high cell turnover [5]. The strains of HIV-1 
can be classified into four groups: the “major” group M, the “outlier” group O and 
two new groups, N and P, representing the four separate introductions of simian 
immunodeficiency virus into humans [6]. The majority (more than 90%) of HIV-1 
infections are caused by HIV-1 group M strains. Within group M there are nine 
genetically distinct subtypes (or clades) of HIV-1. These are subtypes A, B, C, D, F, 
G, H, J and K [7].
1.1 Gender differences in HIV disease progression
HIV disease progression and clinical manifestations of diseases may differ 
between women and men because of biological and socioeconomic factors [8]. 
The progression of AIDS reflects the chronic nature of the disease, the hallmark of 
which is a gradual deterioration of the host immune system. Previous investigations 
found different rates of HIV disease progression and of virological and immu-
nological response to antiretroviral therapy (ART) among HIV-infected women 
compared with men [9]. The rate of increase in viral load over time is presumably 
greater for women than men given that women and men progress to AIDS and death 
at similar rates [10]. Baseline clinical and immunologic status was found to be pre-
dictors of HIV related mortality and morbidity in HIV outcome studies conducted 
in both high income and low-income countries. In the same studies, Men were 
found to have a significant higher rate of loss to follow-up and ART non-adherence 
[11]. More evidence suggests that HIV positive men have worse treatment outcomes 
than their women counterparts in Africa [12]. One study found that humans show 
strong sex differences in immunity to infection and autoimmunity, suggesting sex 
hormones modulate immune responses [13]. Similarly, evaluation of the gender dif-
ference in the outcome of other viral diseases like the COVID-19, revealed a higher 
mortality rate of male patients as compared with female patients, suggesting the 
protective role of estrogen [14].
Some studies have documented the differences in clinical progression of HIV 
between women and men due to hormones and age at the time of HIV infection 
[15], some studies suggesting that the differences in immunological responses to 
ART and mortality risk are due to biologic differences between men and women. 
The hormonal fluctuations in ovulating females, may affect immune function, 
and thus can cause variation on viral loads in women, where HIV RNA levels can 
decrease to a median of 0.16 log10 from the time of early follicular to the mid-luteal 
phase [10]. Studies involving male-to-female transsexuals have shown decrease in 
CCR5 expression when female hormones are administered.
Women living with HIV have limited access to care and treatment in several 
countries, most of who belong to ethnic or racial minorities, despite having better 
treatment outcomes and higher enrolment to ART care when compared to men [12]. 
However, women may delay ART initiation because of social obligations, pregnancy 
and socioeconomic factors [16].
1.2 Problem statement
Highly Active Antiretroviral Therapy (HAART) for treatment of HIV infec-
tion has improved the lives of HIV infected people by reducing the morbidity and 
mortality in patients receiving treatment. This has transformed a chronic fatal 
infectious disease into a manageable chronic infectious disease. Despite the use 
of HAART, numerous reports indicate failure of therapy due to lack of potency of 
some drugs or drug combinations, insufficient drug adherence and transmission 
of drug resistant virus. In a number of patients, HAART is not sufficiently effective 
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thus results into virological, clinical and immunological decay [17]. The success of 
HAART in HIV infected patients may be influenced by other host factors; however, 
there is no enough information with combined assessment of a variety of factors 
that can influence treatment efficacy in clinical routine practice. One of the poorly 
understood factors that may influence disease progression and treatment response 
is gender. Men and women are affected differently with HIV and women’s immune 
systems may respond differently to the virus because of hormonal influence. 
Women may also experience stronger side effects when using ARV drugs, such as 
central nervous system and gastrointestinal symptoms, which could then lower 
their ARV adherence [18]. Survival of HIV infected patient from the point of HIV 
diagnosis to AIDS within a comparable clinical care setting is affected mostly by the 
time of HIV diagnosis (WHO stage I and II), and other differences like age, gender, 
race and behavioral factors may also play a role on survival [19]. Also the differ-
ential use of ARV drugs for purely social economic reasons may lead to survival 
disadvantages for women [10].
Some patients, especially males diagnosed with HIV in developing countries, 
are not always successfully linked to onward treatment services, resulting in delays 
on initiating ART, or prophylaxis for opportunistic infections. Delayed presenta-
tion to care and treatment, and late HIV diagnosis, can result into late initiation 
of ART which affects adherence to treatment and results into poor prognosis in a 
disadvantageous group in the society [20]. More studies will be of benefit to explore 
the possibility of initiating ART at lower viral loads in women, especially during the 
early stages of infection.
1.3 Rationale of the study
As the use of ARV drugs in resource-limited countries increases, it is important 
to understand the effect of several factors on disease progression and outcome of 
ART. Combined analyses of various factors are scarce. Several studies except trials 
on specific regimens, have addressed aspects such as baseline clinical characteristics 
and adherence as predictors of treatment success. For limited resource settings, 
where ARV drugs are not sufficient for all patients, it would be cost effective to 
issue the drugs to patients who will ultimately adhere to the therapy. Cheap alterna-
tive methods are needed, to help in guiding therapy, especially in this era where 
the use of ARV has become widespread. If not controlled, emergence of HIV drug 
resistance will further complicate the epidemiology and transmission patterns of 
HIV especially during the time when ARV resources are limited. Various studies 
came up with different results on the survival difference between male and female 
HIV patients, and some of the differences were a result of inadequate medical 
care rather than biological differences. Some of the differences were related to the 
time to development of AIDS and opportunistic infections, viral load, ARV drug 
resistance and CD4 counts over time of observation. HIV disease progression can 
be determined by viral and host factors and sex differences in immune modula-
tion. The purpose of this study was to assess the socio-demographic and virological 
factors predicting HIV disease progression among HIV patients in Dar es Salaam, 
Tanzania.
2. Methods
We conducted a cohort study in which we followed up HIV-infected ARV naïve 
patients for 1 year. We enrolled ARV naïve, HIV infected patients who were due to 
initiate ART, if they were 18 years and above, with available medical records from 
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previous year. All patients were enrolled after providing written informed consent. 
We used a structured questionnaire to collect social demographic variables and 
anthropometric information, while patient record files and CTC database were 
used to collect data with respect to HIV diagnosis, clinical and ARV treatment 
information.
We categorized patients according to the clinical and performance scales of 
the staging system for HIV-1 patients [21]. The differences on these variables were 
assessed between males and females. All patients were followed up for a period 
of 1 year after starting treatment where treatment outcome was evaluated after 
12 months from the time of initiation of therapy.
Ethical clearance to conduct the study was obtained from the National Institute 
for Medical Research in Tanzania and permission was seek from Hospital adminis-
tration. All patient identifying information was de-linked from the collected data.
We collected blood in EDTA collection tubes, CD4 level was estimated using 
Becton Dickinson FACSCalibur, and viral load using TaqMan Viral-Load Assay 
COBAS® AmpliPrep.
Whole blood was separated by centrifugation at 4000 revolutions per minute 
for 20 minutes at −15°C, and plasma aliquoted and stored for testing. HIV RNA 
was extracted from plasma using Qiagen QIAamp Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. cDNA synthesis was performed using 
SS III RT-PCR System (Life Technologies, USA) according to the manufacturer’s 
instructions with the primers PrtM-F1 and RT-R1. Nested PCR was performed 
from obtained RT-PCR product, using primers Prt-F2 and RT-R2. The QIA quick 
PCR purification kit (Qiagen, Hilden, Germany) was used to purify the nested 
PCR products and quantified by agarose gel visualization. The ABI Prism Big Dye 
Terminator Cycle Sequencing Ready Reaction kit was used for sequencing together 
with the following primers PRT-F2, RT-R2, SeqF3 (35V), SeqR3 (90v1), SeqF4 
(36V) and SeqR4 (AV44). Sequences were aligned using Clustal X [22], manually 
edited with BioEdit [23].
Data were analyzed using Epi Info version 3.5.1 and STATA 11. Clinical progres-
sion was assessed by comparing clinical characteristics at hospital registration, 
baseline and at the time of the study, taking into account the change in clinical 
characteristics over time. Median percentage weight gain was adjusted for amount 
of time on treatment. Gender differences were assessed using the Kruskal-Wallis 
test for continuous variables and the chi-square test for categorical data. Descriptive 
analysis was done for the basic demographic, clinical and immunological charac-
teristics of patients as well as continuous variables like CD4 counts, age, plasma 
viral load levels and BMI for both males and females. Survival distributions for 
male and female patients were estimated using the Kaplan-Meier method. Patients 
who were lost to follow up were censored at the date when they were last seen. 
Patients who were still alive on the date when the study ended were censored on this 
date. Survival times were expressed in days. Cox’s proportional hazards regression 
models were used to assess the associations between patient characteristics and 
outcomes. All other variables were included in multivariable models to assess their 
impact on the association between gender and outcomes.
3. Results
3.1 Sociodemographic characteristics
In a study of 234 patients recruited to initiate ARVs in Tanzania, 164 (70%) 
of them were females and 70 (30%) were males, with a refusal rate of 6 and 25%, 
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respectively. Significantly more males had attended secondary schools than females; 
had a higher income and a better knowledge of ARV use (Table 1). There was no 
significant difference in median age (36 years), alcohol intake and use of traditional 
medicine and use of intravenous drugs (Table 1). Significantly more males tested 
for HIV following a chronic illness, in contrast to females who tested without signs 
of AIDS. Consequently, the disease stage at HIV diagnosis was significantly more 
advanced in males: more males had CD4 count <100 cells/ml at baseline; they had 
a significantly lower Body Mass Index and higher mean Log10 viral load (males 5.5; 
females 5.1) (Table 1).
3.2 Treatment response and disease progression
The prevalence of adherence to ART as measured by consistence in keeping 






Categorical variables N (%) N (%)
Primary level education 156 (95.1) 59 (84.3) 0.005
Above 100 US Dollar monthly income 57 (34.8) 43 (61.4) 0.0002
Having relative to remind to take medication 133 (81.1) 59 (843) 095
Alcohol intake 33 (20.1) 18 (25.7) 04
Use of traditional medicine 97 (592) 45 (652) 05
History of intravenous drug abuse 8 (4.9) 7(10) 02
Knowledge on ARV use and side effects 10 (6.9) 14 (20) 0.005
HIV testing due to chronic illness 105 (64) 55 (78.6) 0.04
Starting treatment with in 1 year of HIV 
diagnosis
130 (793) 55 (78.6) 0.96
Presence of 2 or more opportunistic infections 75 (45.7) 37 (519) 03
WHO staging at initiation of therapy
Stage I 16 (9.8) 5 (7.1) 0.6
Stage II 49 (29.9) 16 (22.9) 0.3
Stage III 82 (50.0) 34 (48.6) 0.8
Stage IV 17(10.4) 15 (21.4) 0.04
CD4 < 100 cells/μl at ART initiation 50 (333)* 31 (47.0)* 0.05
Continuous variables Median (IQR) Median (IQR) P value
Age (Years) 35 (30.5–43.5) 37 (33.5–42.0) 0.38





Continuous variables Mean (SD) Mean (SD) P value
BMI at initiation of therapy 22 (5) 20 (4) 0.002
Log 10 viral load (RNA copies/ml) at initiation 
of therapy
5.1 (1.3) 5.5 (1.1) 0.05
Reproduced with permission from [24].
Table 1. 
Baseline characteristics of 234 HIV-1 infected naïve patients, Dar es Salaam 2010.
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(Table 2). After 1 year of treatment with ART, the virological response was 
significantly better in females than in males (females 69%; males 45% with unde-
tectable viral load) but the mean CD4 increase was significantly higher in males 
(230 cells/ml) than females (202 cells/ml) (Table 3).
The BMI was still significantly higher in females (24.5) compared to males 
(22.5), but the percentage increase of BMI was not significantly different. Also, 
more females (61.6%) survived than males (50%) with more deaths occurring in 
males. The unadjusted relative hazard for death for males at 1 year of ART was 
1.94 with a confidence interval of 0.91 to 4.11, p = 0.08 (Figure 1). Cox propor-
tional hazards (of a model containing social demographic variables) showed 
no significant difference in the survival rate after 1 year on treatment between 
males and females (relative hazard 1.02, 95% CI 0.75, 1.38). The reported 
opportunistic infections during 1 year of follow up were not significantly differ-
ent (Figure 2).
3.3 Genotyping of patients with detectable viral load
A total of 67 patients were found to have detectable viral load at enrolment 
(females 43 (64%); Males 24 (36%)) during 1 year of treatment. Among which, 31 
females and 29 males (60 total), were alive after 1 year of follow up. The status of 
7 could not be confirmed after 1 year of treatment, as they were either died or Loss 
to follow up. The main subtypes identified were C 18 (27%), A 14 (21%) and D 13 
(19%) (Figure 3). There was no significance difference on subtype distribution 
between males and Females.
3.3.1 Nucleoside reverse transcriptase inhibitors (NRTI) resistance mutations
A total of 6 (9%) patients had detected NRTI resistance mutations, 4 females 
and 2 males, among which 3 were alive after 1 year of therapy. There was no signifi-
cance difference between males and females with regard to NRTI resistance muta-
tions. Two of the patients had both NRTI and Protease Inhibitor (PI) resistance 
mutations. One patient-initiated treatment at WHO stage IV, four at WHO stage III 
and one at WHO stage II of disease staging. All patients started treatment with CD4 
below 100 cells/μl and Viral Load above 5000 copies/ml.
3.3.2  Non nucleoside reverse transcriptase inhibitors (NNRTI) resistance 
mutations
A total of 2 (3%) patients had detected NNRTI resistance mutations, all females 
and were alive after 1 year of therapy. One patient-initiated treatment at WHO stage 
Characteristics Females (N = 164) Males (N = 70) P value
N (%) N (%)
Death 21 (12.8) 14 (20) 0.2
Alive 101 (61.6) 35 (50.0) 0.1
Lost to follow up 42 (25.6) 21 (30.0) 0.5
Missed appointments 103 (62.8) 44 (62.9) 0.99
Reproduced with permission from [24].
Table 2. 
One year outcomes of 234 HIV infected patients after starting ART from September 2010 to August 2011.
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III and one at WHO stage II of disease staging. All patients started treatment with 
CD4 below 100 cells/μl and Viral Load above 5000 copies/ml.
3.3.3 Protease inhibitors (PI) resistance mutations
There was no patient with PI major resistance mutations. A total of 15 (22%) 
patients had detected PI minor resistance mutations, 6 females and 9 males, among 
which 6 were alive after 1 year of therapy. There was no significance difference 
between males and females with regard to PI minor resistance mutations. One 
patient-initiated treatment at WHO stage IV, nine at WHO stage III and five at 
WHO stage II of disease staging. Eight patients started treatment with CD4 below 
100 cells/μl and all with Viral Load above 5000 copies/ml.
Characteristics Females (N = 101) Males (N = 53) P value
Percentage with undetectable viral load 70 (69%) 24 (45%) 0.003
Continuous variables Median (IQR) Median (IQR)
CD4 (cells/μl) count after 1 year 312 (252–413) 321 (110–480) 0.6
Continuous variables Mean (SD) Mean (SD)
Percentage BMI increase (from Baseline) 10.5 (14.2) 9.8 (17.5) 0.3
BMI after 1 year 24.5 (4.8) 22.5 (4.1) 0.02
Percentage weight gain 10.4(14.3) 9.3 (17.3) 0.2
CD4 (cells/μl) increase from baseline 202 (516; 35–163) 230 (272; 86–181) 0.05
Reproduced with permission from [24].
Table 3. 
Progression of patients 1 year on ART, Dar es Salaam.
Figure 1. 
Kaplan-Meier survival curves on time to death for 234 patients, Dar es Salaam (reproduced with permission 
from [24]).
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4. Discussion
Our analysis of gender difference found significant clinical and social-demo-
graphic variations between females and males on HIV disease progression after 
1 year of treatment. Overall, females were found to start CTC with higher CD4 
count and BMI, and lower viral loads than males. Similar findings were reported by 
other studies, which found that women had higher CD4 cell count at ART initia-
tion than men [9].
There was no statistical significant difference in survival between males and 
females in our study population after 1 year of follow up; this is in contrast with the 
findings of another study which found better survival among females and less dis-
ease progression among females after 3 years follow up [25]. The difference could be 
Figure 3. 
Subtype distribution of the detected sequences [24].
Figure 2. 
Observed opportunistic infection during 1 year of follow up (reproduced with permission from [24]).
9Gender Differences in Human Immunodeficiency Virus (HIV) Disease Progression and…
DOI: http://dx.doi.org/10.5772/intechopen.92898
due to a shorter follow up (1 year) in our study compared to 3 years. Despite the fact 
that more males died, the ones who survived were found to have higher mean CD4 
increase than females and more females had undetectable plasma viral load. Our 
findings are similar to a study, which found a significant better survival of female 
HIV-1 infected patients on HAART compared to male patients [10].
The fact that women did not fare worse than men is encouraging considering 
that females were found to be less educated with lower monthly income. This is 
consistent with the current data available in Tanzania where males earn more than 
females and are more educated [12]. However, males delayed reporting to care, 
with an advanced disease. Several studies have also indicated differences in health 
seeking behavior, between men and women, where more women were reporting to 
health facilities earlier [26]. This could be a result of differences in social respon-
sibilities giving women more entry points to HIV services, like during pregnancy. 
However, we did not have similar results in this study.
The most common reason for HIV testing was presence of AIDS related 
symptoms, rather than voluntary testing, especially for males, and this denied 
the patients time for care at CTC. Despite the fact that both groups had delayed 
registering for care at CTC, 66% of males understood more about the use of ARVs 
than females. Immune Reconstitution Inflammatory Syndrome (IRIS) was associ-
ated with poor response to HIV patients initiated ART with low CD4 [26], which 
could also have happened to some of the patients in this cohort, as also observed 
in another study that CD4 cell count at ART initiation was a strong predictor of 
mortality [27].
Significant number of patients was using alternative medicines, illicit drugs and 
alcohol prior to starting ARVs, more observed among males than females. The use of 
alternative medicines and alcohol could contribute to the delay in seeking health care 
and late presentation to the care and treatment centers with advanced disease and 
also predispose the patients to poor adherence and poor prognosis [28]. However, 
there was no significant difference on ART adherence as measured by consistency 
in keeping appointment. There was also no significant difference in  development 
of ARV drug resistance mutations. Excessive alcohol consumption can exacerbate 
immunosuppression, enhance the toxicity of ARV on liver cells and accelerating liver 
damage and may also depress the immune system leading to increased multiplication 
of the virus in mononuclear cells [29]. A significant number of patients reported  
use of injection-based illicit drugs in the past and present, this could have implica-
tions on ARV adherence and disease progression. Several studies have associated the 
use of illicit drugs with non-adherence to ART and poor prognosis. People who inject 
drugs (PWID) are also challenged with poor social and economic conditions, mental 
illnesses, which may affect their access and adherence to ART [30].
Women had a lower median viral load at initiation of therapy compared to men, 
despite the fact that there was no much difference on the period of illness before 
starting ART between the two groups. However, after 1 year of treatment, more 
females had undetectable plasma viral load and lower mean CD4 cell increase than 
males. This will need further evaluation, as this may need redefining the time 
to initiate ART in the two groups. Further studies are needed to understand the 
benefits of initiating ART, earlier with lower viral loads. This is because the abso-
lute viral load seems to confer different risks for AIDS between men and women, 
which is not the case with relative viral loads [10]. Because HIV related morbidity 
is influenced by both viral and host factors, sex differences in immune modulation 
will likely play instrumental roles in determining the course of disease. Despite an 
observed high number of both males and females patients presenting with oppor-
tunistic infections; females reported more fever and oral candidiasis than males. 
The reason could be late presentation to CTC and thus could not benefit from the 
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care and treatment services like prophylaxis against opportunistic infections. This 
may predispose the patients to poor prognosis and poor adherence after starting 
treatment [31]. Patients receiving HIV diagnosis late in the course of infection are 
usually more severely immune compromised and are more likely to present with 
co-morbidities like tuberculosis, which may be part of the immune reconstitution 
syndrome.
Consistent with our previous report, the most prevalent subtypes were A, C and 
D, and recombinants [32]. Our study found no contradiction to previous studies 
that found no association between subtype and therapy response, although our 
sample size was too small to conclude that [33].
Of concern was the detection of resistance to the first line ARV in Tanzania, in 
individuals who have been on treatment for only 1 year. This ARV resistance pattern 
was not limited to a particular subtype or gender. We observed minor PI mutations, 
which could be naturally occurring polymorphisms with no clinical significance. 
Interestingly, similar resistance mutations in the protease inhibitor genes were also 
observed in two different studies in Tanzania [34, 35].
5. Conclusion
We assessed the gender differences on HIV disease progression and outcomes 
after 1 year of ART among HIV infected patients and whether this potential dif-
ference is influenced by social, virological and immunological differences among 
patients starting ART. We observed some differences in clinical disease progression 
between males and females before starting ART and after 1 year of treatment. Male 
HIV patients delay seeking care and enter into treatment at a more advanced stage 
of HIV infection, which predisposed them to increased mortality. We also observed 
social factors that can affect future ART success in these patients. We recommend 
continuous follow up of this and other cohort of patients to understand responses to 
ART and the differences between males and females, together with advocating early 
HIV diagnosis and treatment to males. The observed gender difference between 
males and females will need further evaluation, as there may be a need to redefine 
the time to initiate ART in the two groups. The possibility of initiating ART at lower 
viral loads in women, especially during the early stages of infection merits further 
study. We recommend continuous follow up of this and more cohort of patients 
to understand responses to ART and the differences between males and females, 
together with advocating early HIV diagnosis and treatment to males.
It is important to monitor the viral response to patients on ART for early detec-
tion of treatment failure, together with understanding the ARV resistance pattern 
to ART Naïve patients and ART experienced patients. ARV resistance monitoring 
will help avoid unnecessary costs on use of ineffective treatment. The observed 
mutations within the pol region are of considerable concern because they may 
increase the development and spread of ARV resistant strains.
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